Cipla Ltd (The Chemical, Industrial and Pharmaceutical Laboratories) of Mumbai, India has granted distribution rights of their full line of pharmaceutical molecules to the Mexican company “Surtidora Pro-Medical SA de CV located in Puerto Vallarta, Mexico.
This agreement will allow Pro-Medical of Mexico the permission to import, register, distribute, advertise and supply all pharmaceutical products within the Cipla Ltd’s catalog of products. Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla also offers technology for products and processes.
Cipla’s manufacturing facilities have been approved by the following regulatory authorities:
Food and Drug Administration (FDA), USA
Medicines and Healthcare products Regulatory Agency (MHRA), UK
Therapeutic Goods Administration (TGA), Australia
Medicines Control Council (MCC), South Africa
National Institute of Pharmacy (NIP), Hungary
Pharamaceutical Inspection Convention (PIC), Germany
World Health Organisation (WHO) Department of Health, Canada
State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil
This Cipla catalog consist of over 2,100 individual preparations. These molecules are used in the therapy of Alzheimer’s, AIDS/HIV, Cancer, Diabetes, Women’s Health Issues, Men’s Health Issues and many more products in the pipeline.
This joint venture will give Cipla more presence within the Mexico Pharmaceutical markets which is the largest in Latin America along with Brazil and in turn allow Pro-Medical SA de CV to expand it’s imported generic product line. Enabling further expanded distribution within Mexico.
Above story reported by R. Gutierrez Martinez